Latest Period
Q4 2025
Security Snapshot
Jade Biosciences, Inc. - Common Stock (JBIO) Institutional Ownership
CUSIP: 008064206
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
102
Shares (Excl. Options)
47,075,378
Price
$15.43
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- JBIO on Nasdaq
- Shares outstanding
- 48,847,340
- Price per share
- $16.17
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 47,075,378
- Total reported value
- $726,260,386
- % of total 13F portfolios
- 0%
- Share change
- +13,832,194
- Value change
- +$242,240,917
- Number of holders
- 102
- Price from insider filings
- $16.17
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- JBIO - Jade Biosciences, Inc. - Common Stock is tracked under CUSIP 008064206.
- 102 institutions reported positions in Q4 2025.
- 12 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 102 to 23 between Q4 2025 and Q1 2026.
- Reported value moved from $726,260,386 to $37,893,329.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 102 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 008064206?
CUSIP 008064206 identifies JBIO - Jade Biosciences, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 008064206:
Significant Owners of Jade Biosciences, Inc. - Common Stock (JBIO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $89,373,614 | +$26,797,898 | 10,353,875 | +43% | Fairmount Funds Management LLC | 06 Oct 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $70,905,847 | +$26,271,533 | 5,115,862 | +59% | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 |
| FMR LLC | 15% | $40,965,976 | 4,735,951 | FMR LLC | 30 May 2025 | |||
| Bellevue Group AG | 6.8% | $46,307,688 | 3,341,103 | Bellevue Group AG | 16 Dec 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 7% | +72% | $27,758,364 | +$16,318,579 | 3,214,969 | +143% | RA Capital Management, L.P. | 08 Oct 2025 |
| JANUS HENDERSON GROUP PLC | 6.2% | $42,459,514 | 3,063,457 | JANUS HENDERSON GROUP PLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 4.7% | -27% | $32,256,341 | +$2,045,989 | 2,295,825 | +6.8% | BlackRock, Inc. | 31 Mar 2026 |
| VANGUARD GROUP INC | 4.2% | -23% | $32,337,685 | +$4,446,695 | 2,095,767 | +16% | The Vanguard Group | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 4.2% | 0% | $11,949,495 | +$379,228 | 1,384,646 | +3.3% | Frazier Life Sciences Public Fund, L.P. | 30 Sep 2025 |
| Sofinnova Venture Partners X, L.P. | 0.3% | $1,617,308 | 107,391 | Sofinnova Venture Partners X, L.P. ("SVP X") | 28 Apr 2025 | |||
| TCG Crossover GP I, LLC | 0.2% | $649,193 | 64,023 | TCG Crossover GP I, LLC | 28 Apr 2025 | |||
| Atlas Venture Fund XII, L.P. | 0.2% | $521,257 | 51,406 | Atlas Venture Associates XII, L.P. | 28 Apr 2025 |
As of 31 Dec 2025, 102 institutional investors reported holding 47,075,378 shares of Jade Biosciences, Inc. - Common Stock (JBIO). This represents 96% of the company’s total 48,847,340 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Jade Biosciences, Inc. - Common Stock (JBIO) together control 89% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 6,894,488 | +41% | 0.01% | $106,381,950 |
| Fairmount Funds Management LLC | 9.3% | 4,553,494 | +41% | 5.3% | $70,260,412 |
| RA CAPITAL MANAGEMENT, L.P. | 7.5% | 3,671,083 | +246% | 0.58% | $56,644,811 |
| Bellevue Group AG | 6.8% | 3,341,103 | 0.98% | $51,553,219 | |
| VR ADVISER, LLC | 6.6% | 3,220,364 | 0% | 2.5% | $49,690,217 |
| BlackRock, Inc. | 5.9% | 2,870,313 | +33% | 0% | $44,288,930 |
| VANGUARD GROUP INC | 4.3% | 2,095,767 | +21% | 0% | $32,337,685 |
| BAKER BROS. ADVISORS LP | 3.4% | 1,641,137 | 0.15% | $25,322,744 | |
| Remedium Capital Partners, LLC | 3.2% | 1,577,750 | 0% | 14% | $24,345,000 |
| Versant Venture Management, LLC | 3.1% | 1,525,820 | 0% | 16% | $23,543,403 |
| RTW INVESTMENTS, LP | 3% | 1,449,273 | 0% | 0.22% | $22,362,282 |
| Avidity Partners Management LP | 2.9% | 1,400,708 | +24% | 6.2% | $21,612,924 |
| SAMSARA BIOCAPITAL, LLC | 2% | 968,798 | +82% | 1.5% | $14,948,553 |
| Driehaus Capital Management LLC | 1.8% | 887,179 | -29% | 0.09% | $13,689,172 |
| MARSHALL WACE, LLP | 1.8% | 875,273 | +2199% | 0.01% | $13,505,462 |
| Aberdeen Group plc | 1.8% | 867,284 | 0.02% | $13,382,192 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 841,808 | +26% | 0% | $12,991,338 |
| GREAT POINT PARTNERS LLC | 1.7% | 806,273 | +27% | 4% | $12,440,792 |
| Soleus Capital Management, L.P. | 1.6% | 796,744 | 0% | 0.52% | $12,293,760 |
| Affinity Asset Advisors, LLC | 1.5% | 714,956 | +995% | 0.79% | $11,031,771 |
| STATE STREET CORP | 1.3% | 642,921 | +29% | 0% | $9,920,271 |
| Point72 Asset Management, L.P. | 1.1% | 558,474 | 0.01% | $8,617,254 | |
| ORBIMED ADVISORS LLC | 1.1% | 531,163 | 0% | 0.18% | $8,195,845 |
| Opaleye Management Inc. | 0.88% | 427,608 | 0.88% | $6,597,991 | |
| Logos Global Management LP | 0.81% | 395,000 | -37% | 0.41% | $6,094,850 |
Institutional Holders of Jade Biosciences, Inc. - Common Stock (JBIO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,697,023 | $37,893,329 | -$1,606,657 | $14.05 | 23 |
| 2025 Q4 | 47,075,378 | $726,260,386 | +$242,240,917 | $15.43 | 102 |
| 2025 Q3 | 31,617,300 | $272,859,518 | +$407,366 | $8.63 | 74 |
| 2025 Q2 | 31,531,484 | $315,000,764 | +$314,968,047 | $9.99 | 70 |